Clinical trials: Prostate Cancer Stage
Prostate Cancer
Comparing Two Sets of Bladder-Filling Instructions in Treating Patients Undergoing Radiation Therapy For Prostate Cancer. ICORG 05-04
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00949338
- Testing
- pre-procedural preparation
- Where
- Ireland
- Volunteers
- 183 people
- Sponsor
- Cancer Trials Ireland
Adenocarcinoma of the Prostate
A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer
Purpose: To determine the efficacy of BAY 43-9006 in combination with bicalutamide in patients with chemo-naïve hormone-refractory prostate cancer.
- Trial name
- NCT00430235
- Testing
- BAY 43-9006
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer, Hormone Refractory Prostate Cancer
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer.
- Trial name
- NCT00510718
- Testing
- MDV3100
- Where
- 9 sites in United States
- Volunteers
- 140 people
- Sponsor
- Pfizer
Recurrent Ovarian Cancer, HER2-negative
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.
- Conditions
- Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer, TNBC
- Trial name
- HS-10502 (NCT06769425)
- Testing
- HS-10502 + NHA, HS-10502 + HS-20093, HS-10502+ Apatinib
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Castration-resistant Prostate Cancer
Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
PERSEUS1 is an open-label, single arm, phase II trial evaluating the efficacy of Pembrolizumab in metastatic castration resistant prostate cancer (mCRPC) patients (Part A) with a biomarker enrichment stage (Part B) if efficacy is…
- Trial name
- PERSEUS1 (NCT03506997)
- Testing
- Pembrolizumab
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostate Cancer
Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00392535
- Testing
- conventional radiotherapy 74 Gy delivered in 37 fractions, hypofractionated radiation therapy 60 Gy in 20 fractions, hypofractionated radiation therapy 57 Gy in 19 fractions
- Where
- 26 sites in United Kingdom
- Volunteers
- 3,216 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Metastatic Castration-resistant Prostate Cancer
Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open-label, phase II umbrella trial assessing the anti-tumor activity of enfortumab alone and in combination with other anti-cancer agents in subjects with metastatic castration-resistant prostate cancer.
- Trial name
- ENCORE (NCT04754191)
- Testing
- Enfortumab vedotin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Utah
Metastatic Prostate Cancer, Prostate Adenocarcinoma
Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer
The present study aims to optimize the use of systemic therapy relative to local tumor ablation in a prospective randomized clinical trial and to validate the existence and characterize the clinical and pathology phenotype of…
- Trial name
- NCT04031378
- Testing
- Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation, Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months
- Where
- Portugal
- Volunteers
- 100 people
- Sponsor
- Fundacao Champalimaud
Prostate Cancer
Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer
This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by electroporation (EP) in men with biochemically…
- Trial name
- NCT02514213
- Testing
- 2mg INO-5150 and electroporation device CELLECTRA®-5P, 8.5mg INO-5150 and electroporation device CELLECTRA®-5P, 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Inovio Pharmaceuticals
Metastatic Prostate Cancer
Phase II Sunitinib Prog Met AIPC
The purpose of this research study is to find out what effects (good and bad) Sutent has on you and your prostate cancer.
- Trial name
- NCT00599313
- Testing
- Sunitinib
- Where
- 45 sites in United States
- Volunteers
- 36 people
- Sponsor
- US Oncology Research
Prostate Cancer
Adaptive Versus Non-adaptive Radiotherapy and 2 Bladder Filling Instructions for Patients With Intermediate or High Risk Localized Prostate Cancer (ARP)
The study is being done to compare the side effects between two different radiation techniques, standard non-adaptive radiation therapy vs.
- Trial name
- NCT06678126
- Testing
- Prostate and Pelvic Nodes Radiotherapy
- Where
- Canada
- Volunteers
- 104 people
- Sponsor
- Scott Tyldesley
Prostatic Neoplasms, Castration-Resistant
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
Hormone tablets, abiraterone (Zytiga®) and enzalutamide (Xtandi®) are approved to treat advanced prostate cancer. However, even if these drugs are helpful, their effectiveness usually diminishes over time.
- Trial name
- ANZadapt (NCT05393791)
- Testing
- Patient-specific adaptive therapy, Abiraterone acetate, Enzalutamide
- Where
- 19 sites in Australia, Netherlands
- Volunteers
- 168 people
- Sponsor
- Leiden University Medical Center
Prostate Cancer
Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy
The purpose of this trial is to compare two similar treatments for patients diagnosed with prostate cancer. The two treatment arms being compared are: (Standard Arm) hormone therapy, which will prevent the production of the male…
- Trial name
- NCT00175396
- Testing
- Androgen suppression, radiotherapy, Androgen suppression, radiotherapy, iodine 125 brachytherapy
- Where
- Canada
- Volunteers
- 400 people
- Sponsor
- University of British Columbia
Metastatic Castration Resistant Prostate Cancer
Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)
The goal of this clinical trial is to test GT-220F in patients with metastatic castration resistant prostate cancer and learn about the best dose required for further study.
- Trial name
- NCT06866795
- Testing
- GT-220F capsule
- Volunteers
- 42 people
- Sponsor
- Geode Therapeutics Inc.
Prostate Cancer
A Study of SHR-4394 Injection in Subjects With Prostate Cancer
This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4394 injection in subjects with prostate cancer.
- Trial name
- NCT06783829
- Testing
- SHR4394
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Urologic Neoplasms, Prostate Cancer
Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer
Selenium, in the form of inorganic Sodium Selenite, may be useful for treating existing prostate cancer. This idea is based on data from our laboratory showing that 1) prostate cancer cells are more sensitive to Selenium (Sodium…
- Conditions
- Urologic Neoplasms, Prostate Cancer, Prostate Cancer Metastatic Disease
- Trial name
- NCT01155791
- Testing
- Docetaxel, Biosyn, Prednisone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sandy Srinivas
Prostate Cancer
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens.
- Trial name
- NCT00110162
- Testing
- antiandrogen therapy, releasing hormone agonist therapy, orchiectomy
- Where
- 20 sites in Australia, New Zealand
- Volunteers
- 2,000 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostatic Neoplasms
Study to Find Maintenance Dose for Periodic Administration of ASP3550
To find effective doses of ASP3550 on the maintenance of serum testosterone suppression in patients with prostate cancer.
- Trial name
- NCT01261572
- Testing
- degarelix
- Where
- 8 sites in Japan
- Volunteers
- 155 people
- Sponsor
- Astellas Pharma Inc
Prostate Cancer
A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
The purpose of this study is to determine the safety and optimal dosing of intravenous copper chloride and disulfiram in men with metastatic castrate-resistant prostate cancer (CRPC).
- Trial name
- NCT02963051
- Testing
- Copper, Disulfiram, Copper gluconate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Daniel George, MD
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases
This phase II trial is studying how well fluorine F 18 sodium fluoride positron emission tomography (PET) works in evaluating response to dasatinib in patients with prostate cancer and bone metastases.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT00936975
- Testing
- Fluorine F 18 Sodium Fluoride
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.